Are Investors Undervaluing Bioventus (BVS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Jun 9, 2026

Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls

Bioventus NASDAQ: BVS executives outlined the company's portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT.

MarketBeat • Jun 8, 2026

Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 8, 2026

Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference

DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026, at 4:00 p.m. ET.

GlobeNewsWire • Jun 2, 2026

After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS)

The heavy selling pressure might have exhausted for Bioventus (BVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research • Jun 2, 2026

Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Bioventus (BVS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research • May 29, 2026

Is Bioventus (BVS) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • May 21, 2026

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.

Zacks Investment Research • May 18, 2026

Consumer Sentiment Just Crashed Below the Recession Threshold. These 3 Defensive Stocks Under $25 Are Built for What Comes Next

Consumer confidence is breaking down in a way investors have not seen in years. The University of Michigan Consumer Sentiment Index landed at 53.3 in March 2026, sitting below the 60 recessionary threshold, and the latest Surveys of Consumers reading dropped further to 49.8 in April 2026, a 6.6% month-over-month decline matching the trough from June 2022.

24/7 Wall Street • May 14, 2026

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?

The consensus price target hints at a 39% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • May 8, 2026